MedTrace Logo

To Study the Influence of GCSF on Natural History of Acute On Chronic Liver Failure After the Acute Phase

NCT02788240 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2018-02-06

No results posted yet for this study

Summary

All consecutive ACLF (Acute on Chronic Liver failure) patients presenting to the institute of liver and biliary sciences, irrespective of the etiology , who have survived the acute phase (i.e. 90 days of onset of the acute on chronic liver failure) and who are willing to participate in the study would be enrolled. After performing baseline biochemical tests, patients will undergo transjugular liver biopsy (TJLB), HVPG (Hepatic Venous Pressure Gradient), Circulating CD34 cells, Bone marrow aspiration and biopsy (Histopathological and immunohistochemical examination will be done).

Conditions

  • Acute on Chronic Liver Failure

Interventions

DRUG

Peg GCSF

BIOLOGICAL

20% Albumin

DIETARY_SUPPLEMENT

Nutrition

OTHER

Bowel wash

DRUG

Terlipressin 1- 4mg,if indicated

DRUG

Meropenem or Imepenem, if indicated

DRUG

Placebo

Sponsors & Collaborators

  • Institute of Liver and Biliary Sciences, India

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-01
Primary Completion
2017-07-15
Completion
2017-07-15

Countries

  • India

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02788240 on ClinicalTrials.gov